Skip to main content
Premium Trial:

Request an Annual Quote

Structural Genomix in Research Collaboration with Lilly

NEW YORK, April 21 - Structural GenomiX (SGX) said today that it has entered a research collaboration with Eli Lilly based on its 3D structure determination technology.


SGX will apply its technology to several Lilly drug targets to determine their three-dimensional structures and generate data on compounds that bind to the drug targets. SGX will also install its technology for Lilly in a high-throughput structural biology facility the company is planning for protein engineering, crystallization, and structure determination.


"The financial benefits to SGX of both the research collaboration and the technology transfer arrangements are substantial," said SGX CEO Tim Harris in a statement. "Further, Lilly is committed to implementing SGX's gene-to-structure platform in their drug discovery programs. This is not a proof-of-principle deal."


Lilly has committed to supporting the research collaboration for at least two years, with an option to extend to a third year.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.